The WuXi PharmaTech and Mayo Clinic-backed aging disease drug developer floated at the midpoint of its range.
Unity Biotechnology, the US-based aging disease drug developer backed by pharmaceutical companies WuXi PharmaTech and Mayo Clinic, has raised $85m in its initial public offering.
The IPO consisted of 5 million shares issued on the Nasdaq Global Select Market priced at $17 each, at the midpoint of the $16 to $18 range the company set late last month.
Unity will use $10m to $20m of the proceeds to advance its lead product candidate, a musculoskeletal disease treatment called UBX0101,…
